On Friday, Adma Biologics Inc (NASDAQ: ADMA) opened lower -7.88% from the last session, before settling in for the closing price of $21.83. Price fluctuations for ADMA have ranged from $3.60 to $23.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 73.26% annually for the last half of the decade. Company’s average yearly earnings per share was noted 494.23% at the time writing. With a float of $228.45 million, this company’s outstanding shares have now reached $236.39 million.
In an organization with 624 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 48.79%, operating margin of 30.01%, and the pretax margin is 19.16%.
Adma Biologics Inc (ADMA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adma Biologics Inc is 3.36%, while institutional ownership is 88.31%. The most recent insider transaction that took place on Nov 22 ’24, was worth 317,250. In this transaction CFO and Treasurer of this company sold 15,000 shares at a rate of $21.15, taking the stock ownership to the 199,433 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO sold 48,967 for $21.10, making the entire transaction worth $1,033,204. This insider now owns 1,989,007 shares in total.
Adma Biologics Inc (ADMA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 494.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.00% during the next five years compared to 38.68% growth over the previous five years of trading.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Check out the current performance indicators for Adma Biologics Inc (ADMA). In the past quarter, the stock posted a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.44. Likewise, its price to free cash flow for the trailing twelve months is 55.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.28, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.73 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Let’s dig in a bit further. During the last 5-days, its volume was 2.67 million. That was inferior than the volume of 3.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 71.63%. Additionally, its Average True Range was 1.10.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 73.72%, which indicates a significant increase from 25.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.09% in the past 14 days, which was lower than the 79.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.04, while its 200-day Moving Average is $12.57. However, in the short run, Adma Biologics Inc’s stock first resistance to watch stands at $21.36. Second resistance stands at $22.62. The third major resistance level sits at $23.45. If the price goes on to break the first support level at $19.27, it is likely to go to the next support level at $18.44. The third support level lies at $17.18 if the price breaches the second support level.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
There are currently 236,390K shares outstanding in the company with a market cap of 4.38 billion. Presently, the company’s annual sales total 258,220 K according to its annual income of -28,240 K. Last quarter, the company’s sales amounted to 119,840 K and its income totaled 35,910 K.
